MedTrace Logo

Intense Treatment Regimen With Intravitreal Aflibercept Injection

NCT03594461 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-01-10

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of intense dosing for a limited period in patients who demonstrate refractory disease on monthly IAI. Patients will be followed for 52 weeks

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

DRUG

Aflibercept Injection

Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy

Sponsors & Collaborators

  • Vitreous -Retina- Macula Consultants of New York

    lead OTHER

Principal Investigators

  • K. Bailey Freund, MD · Vitreous -Retina- Macula Consultants of New York

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-11
Primary Completion
2020-03-31
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03594461 on ClinicalTrials.gov